Pulmonx Co. (NASDAQ:LUNG) Insider Sells $30,726.20 in Stock

Pulmonx Co. (NASDAQ:LUNGGet Free Report) insider Geoffrey Beran Rose sold 4,586 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total transaction of $30,726.20. Following the completion of the transaction, the insider now owns 295,433 shares in the company, valued at approximately $1,979,401.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Geoffrey Beran Rose also recently made the following trade(s):

  • On Monday, June 24th, Geoffrey Beran Rose sold 1,184 shares of Pulmonx stock. The shares were sold at an average price of $6.16, for a total transaction of $7,293.44.

Pulmonx Stock Up 5.3 %

Shares of Pulmonx stock opened at $7.31 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84. The business has a 50-day moving average of $6.92 and a 200-day moving average of $7.82. The company has a market capitalization of $283.74 million, a PE ratio of -4.75 and a beta of 0.63.

Analyst Ratings Changes

LUNG has been the topic of several research reports. Canaccord Genuity Group raised their price objective on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company dropped their target price on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Finally, Lake Street Capital began coverage on Pulmonx in a report on Tuesday, June 4th. They issued a “buy” rating and a $12.00 price target for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

Read Our Latest Analysis on LUNG

Institutional Investors Weigh In On Pulmonx

A number of hedge funds have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC purchased a new position in shares of Pulmonx during the 2nd quarter valued at approximately $477,000. Mackenzie Financial Corp acquired a new stake in Pulmonx in the second quarter valued at $102,000. Deerfield Management Company L.P. Series C boosted its stake in Pulmonx by 134.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 47,539 shares of the company’s stock valued at $301,000 after acquiring an additional 27,250 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Pulmonx during the 2nd quarter valued at $37,000. Finally, Squarepoint Ops LLC grew its holdings in Pulmonx by 261.2% during the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock worth $916,000 after acquiring an additional 104,432 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

(Get Free Report)

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

See Also

Insider Buying and Selling by Quarter for Pulmonx (NASDAQ:LUNG)

Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.